logo RIMA
logo UFRRJ

  1. Repositório de Múltiplos Acervos da UFRRJ
  2. Teses e Dissertações
  3. Programa de Pós-Graduação em Ciências Veterinárias
  4. Doutorado em Ciências Veterinárias
Please use this identifier to cite or link to this item: https://rima.ufrrj.br/jspui/handle/20.500.14407/20193
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPadilla Barreto, Monica Yamile-
dc.date.accessioned2025-02-25T12:03:13Z-
dc.date.available2025-02-25T12:03:13Z-
dc.date.issued2023-03-03-
dc.identifier.citationPADILLA B, Monica Yamile. Aspectos clínicos e epidemiológicos do mastocitoma em caninos atendidos no serviço de oncologia da Universidade Federal Rural Do Rio De Janeiro entre os anos 2011 e 2019. 2023. 117 f. Tese (Doutorado em Ciências Veterinárias) - Instituto de Veterinária, Universidade Federal Rural do Rio de Janeiro, Seropédica, 2023.pt_BR
dc.identifier.urihttps://rima.ufrrj.br/jspui/handle/20.500.14407/20193-
dc.description.abstractO mastocitoma é o tumor cutâneo maligno mais comum em cães, sendo classificado como um tumor de células redondas que pode manifestar-se clinicamente como formações cutâneas de diferentes tamanhos e aspectos. Fatores como localização, sinais clínicos associados ao tumor, taxa de crescimento, tamanho, presença de síndromes paraneoplásicas, raça, sexo e estadiamento clínico podem influenciar o prognóstico. Como os estudos epidemiológicos no Brasil são escassos, objetivou-se com estudo avaliar a distribuição das características clínicas do mastocitoma e analisar o risco de desenvolvimento dessa neoplasia em relação a outros tumores cutâneos nos pacientes atendidos pelo serviço de oncologia do Hospital Veterinário da Universidade Federal Rural do Rio de Janeiro. O estudo epidemiológico retrospectivo incluiu 266 cães afetados por mastocitomas cutâneos com um grupo de referência de 581 pacientes diagnosticados com outros tumores cutâneos; a média da idade dos pacientes foi de 9 anos, sendo as fêmeas mais acometidas que os machos; a maior parte dos pacientes foram cães sem raça definida, seguido da raça Boxer, Labrador, Pitbull e Pinscher; os sinais clínicos como vomito, melena, prurido, caquexia, hemorragia, diarreia, convulsões, síncope, hematomas na pele e prostração foram encontrados em 14,3% dos pacientes. A regiões corporais mais afetadas foram o tronco e os membros pélvicos. Anemia, eosinofilia e trombocitopenia foram alterações comuns nos cães afetados; a cirurgia foi o tratamento escolhido para a maior parte dos pacientes e o protocolo quimioterápico de vimblastina com prednisolona o mais utilizado. Foi identificada predisposição nas raças Boxer, Pinscher, Pug, Bulldog francês e Sharpei contrário às raças Poodle, Cocker Spaniel e Rottweiler que apresentaram um risco menor de desenvolver mastocitoma. Os cães sem raça definida de mediano porte são mais predispostos a desenvolver mastocitoma nos membros em comparação com outros tumores da pele. A sobrevida dos pacientes depende de muitos fatores como o estágio clínico, o grau histopatológico, presença de sinais paraneoplásicas, tipo de tratamento e presença de doenças concomitantes. Este é o primeiro estudo retrospectivo no Brasil que analisa tanto fatores epidemiológicos como clínicos de cães com mastocitoma.pt_BR
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESpt_BR
dc.languageporpt_BR
dc.publisherUniversidade Federal Rural do Rio de Janeiropt_BR
dc.subjectmastocitomapt_BR
dc.subjectneoplasiapt_BR
dc.subjectmetástasept_BR
dc.subjectpredisposiçãopt_BR
dc.subjectrisco de desenvolvimentopt_BR
dc.subjectmast cell tumorpt_BR
dc.subjectneoplasmpt_BR
dc.subjectmetastasispt_BR
dc.subjectpredispositionpt_BR
dc.subjectrisk of developmentpt_BR
dc.titleAspectos clínicos e epidemiológicos do mastocitoma em caninos atendidos no serviço de oncologia da Universidade Federal Rural Do Rio De Janeiro entre os anos 2011 e 2019pt_BR
dc.title.alternativeClinical and epidemiological aspects of mast cell tumor in dogs treated at the oncology service of the Federal Rural University of Rio De Janeiro between 2011 and 2019en
dc.typeTesept_BR
dc.description.abstractOtherMast cell tumor is the most common malignant skin tumor in dogs, being classified as a round cell tumor that can manifest clinically as skin formations of different sizes and appearances. Factors such as location, clinical signs associated with the tumor, growth rate, size, presence of paraneoplastic syndromes, breed, sex, and clinical staging can influence the prognosis. Epidemiological studies in Brazil are scarce, so the objective of this study was to evaluate the distribution of clinical characteristics of mast cell tumor and analyze the risk of developing this neoplasm in relation to other skin tumors in patients attended by the oncology service of the Veterinary Hospital of the University Federal Rural of Rio de Janeiro. The retrospective epidemiological study included 266 dogs affected by cutaneous mast cell tumors with a reference group of 581 patients diagnosed with other cutaneous tumors; the mean age of the patients was 9 years, with females being more affected than males; most of the patients were mongrel dogs, followed by Boxer, Labrador, Pitbull and Pinscher; clinical signs such as vomiting, melena, pruritus, cachexia, hemorrhage, diarrhea, seizures, syncope, skin hematomas and prostration were found in 14.3% of patients. The most affected body regions were the trunk and pelvic limbs. Anemia, eosinophilia, and thrombocytopenia were common changes in affected dogs; surgery was the treatment chosen for most patients and the chemotherapy protocol of vinblastine with prednisolone was the most used. A predisposition was identified in the Boxer, Pinscher, Pug, French Bulldog and Sharpei breeds, contrary to the Poodle, Cocker Spaniel and Rottweiler breeds that presented a lower risk of developing mast cell tumor. Medium-sized mongrel dogs are more likely to develop mast cell tumors in the limbs compared to other skin tumors. Survival of patients depends on many factors such as clinical stage, histopathological grade, presence of paraneoplastic signs, type of treatment and presence of concomitant diseases. This is the first retrospective study in Brazil that analyzes both epidemiological and clinical factors in dogs with mast cell tumor.en
dc.contributor.advisor1Fernandes, Julio Israel-
dc.contributor.advisor1IDhttps://orcid.org/0000-0002-6936-1774pt_BR
dc.contributor.advisor1Latteshttp://lattes.cnpq.br/9221592908532393pt_BR
dc.contributor.referee1Fernandes, Julio Israel-
dc.contributor.referee1IDhttps://orcid.org/0000-0002-6936-1774pt_BR
dc.contributor.referee1Latteshttp://lattes.cnpq.br/9221592908532393pt_BR
dc.contributor.referee2Bendas, Alexandre José Rodrigues-
dc.contributor.referee2IDhttps://orcid.org/0000-0003-4320-9923pt_BR
dc.contributor.referee2Latteshttp://lattes.cnpq.br/5357706483520041pt_BR
dc.contributor.referee3Silva, Bruno Ricardo Soares Alberigi da-
dc.contributor.referee3IDhttps://orcid.org/0000-0002-5707-2203pt_BR
dc.contributor.referee3Latteshttp://lattes.cnpq.br/5366748874483915pt_BR
dc.contributor.referee4Dutra, Ary Elias Aboud-
dc.contributor.referee4Latteshttp://lattes.cnpq.br/1006126664981323pt_BR
dc.contributor.referee5Cardilli, Carolina Franchi João-
dc.contributor.referee5Latteshttp://lattes.cnpq.br/1743045211710725pt_BR
dc.creator.Latteshttp://lattes.cnpq.br/7767273142046558pt_BR
dc.publisher.countryBrasilpt_BR
dc.publisher.departmentInstituto de Veterináriapt_BR
dc.publisher.initialsUFRRJpt_BR
dc.publisher.programPrograma de Pós-Graduação em Ciências Veterináriaspt_BR
dc.relation.referencesACEINO, A. et al. Systemic mastocytosis with subcutaneous hemorrhage and edema in a Greyhound dog: case report and review of diagnostic criteria. Journal of Veterinary Diagnostic Investigation, v. 33, n. 1, p. 95–100, 9 jan. 2021. AKIYOSHI, M. et al. Precursor‐targeted immune‐mediated anemia in a dog with a stage IV mast cell tumor and bone marrow infiltration. Veterinary Clinical Pathology, v. 50, n. 1, p. 151–157, 2 mar. 2021. ALVAREZ, L.; WHITTEMORE, J. C. Liver Enzyme Elevations in Dogs: Physiology and Pathophysiology. Compendium, n. September, 2009. ARENDT, M. L. et al. Genome-Wide Association Study of Golden Retrievers Identifies Germ- Line Risk Factors Predisposing to Mast Cell Tumours. PLOS Genetics, v. 11, n. 11, p. e1005647, 20 nov. 2015. BADILLO, M. et al. Infection by Ehrlichia canis and Anaplasma sp . in dogs attended in veterinary clinics , Barranquilla , Colombia. Revista MVZ Córdoba, v. 22, p. 6023–6033, 2017. BAE, S. et al. Histologically low‐grade, yet biologically high‐grade, canine cutaneous mast cell tumours: A systematic review and meta‐analysis of individual participant data. Veterinary and Comparative Oncology, v. 18, n. 4, p. 580–589, 10 dez. 2020. BEER, P. et al. The role of sentinel lymph node mapping in small animal veterinary medicine: A comparison with current approaches in human medicine. Veterinary and Comparative Oncology, v. 16, n. 2, p. 178–187, jun. 2018. 83 BELLAMY, E.; BERLATO, D. Canine cutaneous and subcutaneous mast cell tumours: a narrative review. Journal of Small Animal Practice, v. 63, n. 7, p. 497–511, 20 jul. 2022. BERGMAN, P. J. et al. Correlation of histologic grading of canine mast cell tumors with Ki67/PCNA/AgNOR/c-Kit scores: 38 cases (2002-2003). Veterinary and Comparative Oncology, v. 2, n. 2, p. 98–98, jun. 2004. BERLATO, D. et al. Comparison of mitotic index and Ki67 index in the prognostication of canine cutaneous mast cell tumours. Veterinary and Comparative Oncology, v. 13, n. 2, p. 143–150, jun. 2013. BERLATO, D. et al. Value, Limitations, and Recommendations for Grading of Canine Cutaneous Mast Cell Tumors: A Consensus of the Oncology-Pathology Working Group. Veterinary Pathology, v. 58, n. 5, p. 858–863, 23 set. 2021. BIASOLI, D. et al. A synonymous germline variant in a gene encoding a cell adhesion molecule is associated with cutaneous mast cell tumour development in Labrador and Golden Retrievers. PLOS Genetics, v. 15, n. 3, p. e1007967, 22 mar. 2019. BLACKWOOD, L. et al. European consensus document on mast cell tumours in dogs and cats. Veterinary and Comparative Oncology, v. 10, n. 3, p. e1–e29, set. 2012. BONKOBARA, M. Dysregulation of tyrosine kinases and use of imatinib in small animal practice. The Veterinary Journal, v. 205, n. 2, p. 180–188, ago. 2015. BOSTOCK, D. E. The prognosis following surgical removal of mastocytomas in dogs. Journal of Small Animal Practice, v. 14, n. 1, p. 27–40, jan. 1973. BRAUND, K. G. et al. Peripheral Neuropathy Associated with Malignant Neoplasms in Dogs. Veterinary Pathology, v. 24, n. 1, p. 16–21, 1987. BRAZ, P. H. et al. Comparação entre a citopatologia por biopsia com agulha fina e a histopatologia no diagnóstico das neoplasias cutâneas e subcutâneas de cães. Pesquisa Veterinária Brasileira, v. 36, n. 3, p. 197–203, mar. 2016. BRAZ, P. H. et al. Classificação citológica do grau de malignidade de mastocitomas em cães. Pubvet, v. 11, n. 11, p. 1114–1118, 2018. BRLOZNIK, M. et al. Results of Dynamic Contrast-Enhanced Ultrasound Correlate With Treatment Outcome in Canine Neoplasia Treated With Electrochemotherapy and Interleukin- 84 12 Plasmid Electrotransfer. Frontiers in Veterinary Science, v. 8, n. 679063, p. 1–12, 20 maio 2021. BROWN, G. K. et al. Intratumoural Treatment of 18 Cytologically Diagnosed Canine High- Grade Mast Cell Tumours With Tigilanol Tiglate. Frontiers in Veterinary Science, v. 8, 27 ago. 2021. BROWN, M. et al. Utility of Spleen and Liver Cytology in Staging of Canine Mast Cell Tumors. Journal of the American Animal Hospital Association, v. 58, n. 4, p. 168–175, 1 jul. 2022. BURTON, J. H. et al. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs. Journal of Veterinary Internal Medicine, v. 29, n. 4, p. 1098–1104, jul. 2015. CAMPS-PALAU, M. A. . et al. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997 – 2004). Veterinary and Comparative Oncology, v. 5, n. 3, p. 156–167, 2007. CAMUS, M. S. et al. Cytologic Criteria for Mast Cell Tumor Grading in Dogs With Evaluation of Clinical Outcome. Veterinary Pathology, v. 53, n. 6, p. 1117–1123, 2016. CARTAGENA-ALBERTUS, J. C. et al. Presumptive primary intrathoracic mast cell tumours in two dogs. BMC Veterinary Research, v. 15, n. 1, p. 204, 17 dez. 2019. CARVALHO, A. P. M. DE et al. Estudo retrospectivo do mastocitoma cutâneo canino utilizando duas classificações histopatológicas. Brazilian Journal of Veterinary Medicine, v. 39, n. 3, p. 170–175, 2017. CASTRO NEVES, C. et al. Mastocitoma canino -estudo retrospectivo de 25 casos canine. Revista Científica Eletrônica De Medicina Veterinária, v. 1814, n. 1679–7353, p. 17400– 0, 2012. CAVALCANTE, I. M. S. et al. a Retrospective Study of Canine Cutaneous Mast Cell Tumor: Correlation Between Clinical, Histological and Molecular Characteristics/ Um Estudo Retrospectivo De Mastócitos Cutâneos Caninos: Correlação Entre Características Clínicas, Histológicas E Molecula. Brazilian Journal of Development, v. 6, n. 12, p. 100281–100299, 2020. CEMAZAR, M. et al. Intramuscular IL-12 Electrogene Therapy for Treatment of Spontaneous 85 Canine Tumors. In: Targets in Gene Therapy. [s.l.] InTech, 2011. CEMAZAR, M. et al. Efficacy and safety of electrochemotherapy combined with peritumoral IL‐12 gene electrotransfer of canine mast cell tumours. Veterinary and Comparative Oncology, v. 15, n. 2, p. 641–654, 3 jun. 2017. CHAFFIN, K.; THRALL, D. E. RESULTS OF RADIATION THERAPY IN 19 DOGS WITH CUTANEOUS MAST CELL TUMOR AND REGIONAL LYMPH NODE METASTASIS. Veterinary Radiology, v. 43, n. 4, p. 392–395, jul. 2002. CHEN, P. et al. Mutations in Exons 8 and 11 of c-kit Gene in Canine Subcutaneous Mast Cell Tumors and Their Association with Cell Proliferation. Veterinary Sciences, v. 9, n. 9, p. 493, 10 set. 2022. CHU, M. L. et al. Comparison of lateral surgical margins of up to two centimeters with margins of three centimeters for achieving tumor-free histologic margins following excision of grade I or II cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association, v. 256, n. 5, p. 567–572, 1 mar. 2020. CIFUENTES-ARIAS, S.; OSORIO-MORALES, L.; PEDRAZA-ORDÓÑEZ, F. Clinical follow-up of canine mast cell tumour cases diagnosed by cytology and histopathology. Veterinarska stanica, v. 52, n. 4, p. 397–403, 22 fev. 2021. COOPER, M.; TSAI, X.; BENNETT, P. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Veterinary and Comparative Oncology, v. 7, n. 3, p. 196–206, set. 2009. CORTADELLAS, O.; FERNÁNDEZ, M. Diagnóstico y tratamiento de la enfermedad renal crónica (ERC) en el perro y el gato. Clínica veterinaria de pequeños animales: revista oficial de AVEPA, Asociación Veterinaria Española de Especialistas en Pequeños Animales, v. 32, n. 4, p. 215–223, 2012. COSTA-CASAGRANDE, T. et al. Estudo retrospectivo do mastocitoma canino no serviço de cirurgia de pequenos animais – hospital veterinário da faculdade de medicina veterinária e zootecnia da universidade de São Paulo. Archives of Veterinary Science, v. 13, n. 3, p. 176– 183, 2008. COSTA, M. C. et al. Prevalence and epidemiological and histopathological features of canine cutaneous mast cell tumours in Uberlândia, Brazil. Acta Veterinaria Brno, v. 86, n. 2, p. 189– 86 193, 2017. CUNTO, M.; BALLOTTA, G.; ZAMBELLI, D. Benign prostatic hyperplasia in the dog. Animal Reproduction Science, v. 247, p. 107096, dez. 2022. DANTAS-TORRES, F. et al. Prevalence and incidence of vector-borne pathogens in unprotected dogs in two Brazilian regions. Parasites & Vectors, v. 13, n. 1, p. 195, 21 dez. 2020. DAVIES, D. R. et al. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. Journal of the American Animal Hospital Association, v. 40, n. 2, p. 124– 130, 2004. DE BIASE, D. et al. RNAScope in situ Hybridization as a Novel Technique for the Assessment of c-KIT mRNA Expression in Canine Mast Cell Tumor. Frontiers in Veterinary Science, v. 8, n. 591961, p. 1–9, 16 fev. 2021. DE NARDI, A. B. et al. Brazilian Consensus for the Diagnosis, Treatment and Prognosis of Cutaneous Mast Cell Tumors in Dogs. Investigação, v. 17, n. 1, p. 1–15, 2018. DE RIDDER, T. et al. Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours. Frontiers in Veterinary Science, v. 8, 15 dez. 2021a. DE RIDDER, T. R. et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate. Journal of Veterinary Internal Medicine, v. 35, n. 1, p. 415–429, 16 jan. 2021b. DIAS-PEREIRA, P. Morbidity and mortality in elderly dogs – a model for human aging. BMC Veterinary Research, v. 18, n. 1, p. 457, 29 dez. 2022. DONNELLY, L. et al. Evaluation of histological grade and histologically tumour-free margins as predictors of local recurrence in completely excised canine mast cell tumours. Veterinary and Comparative Oncology, v. 13, n. 1, p. 70–76, mar. 2015. ELSTON, L. B. et al. The importance of the mitotic index as a prognostic factor for survival of canine cutaneous mast cell tumors: a validation study. Veterinary pathology, v. 46, n. 2, p. 362–4, author reply 364-5, mar. 2009. EZE, U. U. et al. Prevalence of Increased Serum Urea and Creatinine Levels in Dogs. Notulae 87 Scientia Biologicae, v. 11, n. 3, p. 340–346, 30 set. 2019. FERRARI, R. et al. The impact of extirpation of non-palpable/normal-sized regional lymph nodes on staging of canine cutaneous mast cell tumours: A multicentric retrospective study. Veterinary and Comparative Oncology, v. 16, n. 4, p. 505–510, dez. 2018. FONSECA-ALVES, C. E. et al. Ki67/KIT double immunohistochemical staining in cutaneous mast cell tumors from Boxer dogs. Research in Veterinary Science, v. 102, p. 122–126, out. 2015. FOURNIER, Q. et al. Contrast‐enhanced ultrasound for sentinel lymph node mapping in the routine staging of canine mast cell tumours: A feasibility study. Veterinary and Comparative Oncology, v. 19, n. 3, p. 451–462, 11 set. 2021. FURLANI, J. M. et al. Mastocitoma Canino: Estudo Retrospectivo. Ciência Animal Brasileira, v. 9, n. 1, p. 242–250, 2008. GAMPERL, S. et al. Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells. Veterinary and Comparative Oncology, v. 17, n. 4, p. 553–561, 13 dez. 2019. GARCÍA, S. M. Mastocitoma. In: CARTAGENA ALBERTUS, J. C. (Ed.). . Oncología veterinaria-Manuales clínicos por especialidades. Navarra: [s.n.]. p. 101–116. GARIBOLDI, E. M. et al. Sentinel Lymph Node Biopsy Is Feasible in Dogs with Scars from Prior Local Excision of Solid Malignancies. Animals, v. 12, n. 17, p. 2195, 26 ago. 2022. GARRETT, L. Canine mast cell tumors: diagnosis, treatment, and prognosis. Veterinary Medicine: Research and Reports, v. 5, p. 49–58, ago. 2014. GIANTIN, M. et al. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors. Journal of Veterinary Diagnostic Investigation, v. 24, n. 1, p. 116–126, 6 jan. 2012a. GIANTIN, M. et al. Expression of Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases and Vascular Endothelial Growth Factor in Canine Mast Cell Tumours. Journal of Comparative Pathology, v. 147, n. 4, p. 419–429, nov. 2012b. GRANT, I. A. et al. A Phase II Clinical Trial of Vinorelbine in Dogs with Cutaneous Mast Cell Tumors. Journal of Veterinary Internal Medicine, v. 22, n. 2, p. 388–393, mar. 2008. 88 GRANT, J.; NORTH, S.; LANORE, D. Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours. Journal of Small Animal Practice, v. 57, n. 6, p. 283–290, jun. 2016. GRIMES, J. A. et al. Use of indirect computed tomography lymphangiography to determine metastatic status of sentinel lymph nodes in dogs with a pre‐operative diagnosis of melanoma or mast cell tumour. Veterinary and Comparative Oncology, v. 18, n. 4, p. 818–824, 30 dez. 2020. GRINDEM, C. B. et al. Thrombocytopenia Associated With Neoplasia in Dogs. Journal of Veterinary Internal Medicine, v. 8, n. 6, p. 400–405, nov. 1994. HAHN, K. A. et al. Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors. Journal of Veterinary Internal Medicine, v. 22, n. 6, p. 1301–1309, nov. 2008. HARRUS, S.; WANER, T. Diagnosis of canine monocytotropic ehrlichiosis (Ehrlichia canis): An overview. The Veterinary Journal, p. 292–296, 2011. HART, B. L. et al. Long-Term Health Effects of Neutering Dogs: Comparison of Labrador Retrievers with Golden Retrievers. PLoS ONE, v. 9, n. 7, p. e102241, 14 jul. 2014. HART, B. L. et al. Neutering of German Shepherd Dogs: associated joint disorders, cancers and urinary incontinence. Veterinary Medicine and Science, v. 2, n. 3, p. 191–199, 16 ago. 2016. HAY, J. K.; LARSON, V. S. Lomustine (CCNU) and prednisone chemotherapy for high-grade completely excised canine mast cell tumors. Canadian Veterinary Journal, v. 60, n. 12, p. 1326–1330, 2019. HORTA, R. S. et al. Outcome of adjuvant chemotherapy with lomustine, vinblastine and chlorambucil on management of canine mast cell tumour of high to intermediate risk. Arquivo Brasileiro de Medicina Veterinária e Zootecnia, v. 69, n. 6, p. 1426–1436, nov. 2017. HORTA, R. S. et al. Assessment of Canine Mast Cell Tumor Mortality Risk Based on Clinical, Histologic, Immunohistochemical, and Molecular Features. Veterinary Pathology, v. 55, n. 2, p. 212–223, 16 mar. 2018. HOSOYA, K. et al. Adjuvant CCNU (Lomustine) and Prednisone Chemotherapy for Dogs With Incompletely Excised Grade 2 Mast Cell Tumors. Journal of the American Animal Hospital Association, v. 45, n. 1, p. 14–18, jan. 2009. 89 HWANG, C. C. et al. Oncolytic Reovirus in Canine Mast Cell Tumor. PLoS ONE, v. 8, n. 9, p. e73555, 20 set. 2013. HWANG, C. C. et al. Reovirus changes the expression of anti-apoptotic and proapoptotic proteins with the c-kit downregulation in canine mast cell tumor cell lines. Biochemical and Biophysical Research Communications, v. 517, n. 2, p. 233–237, set. 2019. IARC, W. G. ON THE E. OF C. R. TO H. P. Chlorambucil. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 100A. ed. Lyon: [s.n.]. p. 47. ILYINSKAYA, G. V. et al. Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study). Frontiers in Veterinary Science, v. 5, 4 jun. 2018. ISOTANI, M. et al. Effect of Tyrosine Kinase Inhibition by Imatinib Mesylate on Mast Cell Tumors in Dogs. Journal of Veterinary Internal Medicine, v. 22, n. 4, p. 985–988, jul. 2008. ITOH, T. et al. Long-term postsurgical outcomes of mast cell tumors resected with a margin proportional to the tumor diameter in 23 dogs. Journal of Veterinary Medical Science, v. 83, n. 2, p. 230–233, 2021. JONES, P. D. et al. Recurrence‐free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate. Journal of Veterinary Internal Medicine, v. 35, n. 1, p. 451–455, 22 jan. 2021. KAMSTOCK, D. A. et al. Recommended Guidelines for Submission, Trimming, Margin Evaluation, and Reporting of Tumor Biopsy Specimens in Veterinary Surgical Pathology. Veterinary Pathology, v. 48, n. 1, p. 19–31, 1 jan. 2011. KEENE, B. W. et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. Journal of Veterinary Internal Medicine, v. 33, n. 3, p. 1127–1140, 11 maio 2019. KIM, H.; KIM, J. Successful long-term management with toceranib phosphate of a recurrent muzzle mast cell tumour in a dog. Veterinární Medicína, v. 65, n. No. 5, p. 227–232, 27 maio 2020. KIM, J. et al. Successful response to imatinib in two dogs with inoperable grade III infiltrating mast cell tumours: a case report. Veterinární Medicína, v. 61, n. No. 8, p. 467–473, 10 mar. 2017. 90 KIUPEL, M. et al. The Use of KIT and Tryptase Expression Patterns as Prognostic Tools for Canine Cutaneous Mast Cell Tumors. Veterinary Pathology, v. 41, n. 4, p. 371–377, 26 jul. 2004. KIUPEL, M. et al. Impact of Tumour Depth, Tumour Location and Multiple Synchronous Masses on the Prognosis of Canine Cutaneous Mast Cell Tumours. Journal of Veterinary Medicine Series A, v. 52, n. 6, p. 280–286, ago. 2005. KIUPEL, M. et al. Proposal of a 2-Tier Histologic Grading System for Canine Cutaneous Mast Cell Tumors to More Accurately Predict Biological Behavior. Veterinary Pathology, v. 48, n. 1, p. 147–155, 9 jan. 2011. KIUPEL, M.; CAMUS, M. Diagnosis and Prognosis of Canine Cutaneous Mast Cell Tumors. Veterinary Clinics of North America: Small Animal Practice, v. 49, n. 5, p. 819–836, set. 2019. KLUTHCOVSKY, L. C. et al. Comparison of Two Different Vinblastine Dosages for Treatment of Cutaneous Mast Cell Tumor in Dogs. Acta Scientiae Veterinariae, v. 48, 23 jan. 2020. KOBAYASHI, M. et al. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy. The Veterinary Journal, v. 193, n. 1, p. 264–267, jul. 2012. KODRE, V. et al. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours. In Vivo, v. 23, n. 1, p. 55–62, 2009. KU, C.-K.; KASS, P. H.; CHRISTOPHER, M. M. Cytologic-histologic concordance in the diagnosis of neoplasia in canine and feline lymph nodes: a retrospective study of 367 cases. Veterinary and Comparative Oncology, v. 15, n. 4, p. 1206–1217, dez. 2017. LADUE, T. et al. RADIATION THERAPY FOR INCOMPLETELY RESECTED CANINE MAST CELL TUMORS. Veterinary Radiology, v. 39, n. 1, p. 57–62, jan. 1998. LADUE, T.; KLEIN, M. K. TOXICITY CRITERIA OF THE VETERINARY RADIATION THERAPY ONCOLOGY GROUP. Veterinary Radiology, v. 42, n. 5, p. 475–476, set. 2001. LAPSLEY, J. et al. Influence of locoregional lymph node aspiration cytology vs sentinel lymph node mapping and biopsy on disease stage assignment in dogs with integumentary mast cell tumors. Veterinary Surgery, v. 50, n. 1, p. 133–141, 10 jan. 2021. 91 LEACH, T. N. et al. Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer. Veterinary and Comparative Oncology, v. 10, n. 2, p. 102–112, jun. 2012. LEFEBVRE, S. L. et al. Effect of age at gonadectomy on the probability of dogs becoming overweight. Journal of the American Veterinary Medical Association, v. 243, n. 2, p. 236– 243, 15 jul. 2013. LEIDINGER, E. F. et al. Breed related odds ratio and anatomic distribution of canine mast cell tumours in Austria. Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere, v. 42, n. 06, p. 367–373, 8 jan. 2014. LEJEUNE, A. et al. Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012). Veterinary and Comparative Oncology, v. 13, n. 3, p. 267–280, set. 2015. LEWIS, T. W. et al. Longevity and mortality in Kennel Club registered dog breeds in the UK in 2014. Canine Genetics and Epidemiology, v. 5, n. 1, p. 10, 17 dez. 2018. LIPTAK, J. M.; BOSTON, S. E. Nonselective Lymph Node Dissection and Sentinel Lymph Node Mapping and Biopsy. Veterinary Clinics of North America: Small Animal Practice, v. 49, n. 5, p. 793–807, set. 2019. LONDON, C. A. et al. Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit. Experimental Hematology, v. 27, n. 4, p. 689–697, abr. 1999. LONDON, C. A. et al. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. Clinical Cancer Research, v. 9, n. 7, p. 2755–68, 2003. LONDON, C. A. et al. Multi-center, Placebo-controlled, Double-blind, Randomized Study of Oral Toceranib Phosphate (SU11654), a Receptor Tyrosine Kinase Inhibitor, for the Treatment of Dogs with Recurrent (Either Local or Distant) Mast Cell Tumor Following Surgical Excision. Clinical Cancer Research, v. 15, n. 11, p. 3856–3865, 1 jun. 2009. LONDON, C. A.; THAMM, D. H. Mast Cell Tumors. In: VAIL, D. M.; THAMM, D. H.; LIPTAK, J. M. (Eds.). . Withrow & MacEwen’s Small Animal Clinical Oncology. 6th. ed. St. Louis: Elsevier, 2020. p. 382–403. LOWE, R. et al. The treatment of canine mast cell tumours with electrochemotherapy with or 92 without surgical excision. Veterinary and Comparative Oncology, v. 15, n. 3, p. 775–784, set. 2017. MACEDO, T. R. et al. Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone. Cells, v. 11, n. 3, p. 571, 7 fev. 2022. MACFARLANE, M. J. et al. Use of neutrophil to lymphocyte ratio for predicting histopathological grade of canine mast cell tumours. Veterinary Record, v. 179, n. 19, p. 491– 491, nov. 2016. MACHADO, G. A. C. et al. Incidence of skin tumors in dogs in Salvador, Bahia state, Brazil (2007-2016). Pesquisa Veterinária Brasileira, v. 38, n. 11, p. 2139–2145, nov. 2018. MACKOWIAK, I. I. et al. E-cadherin in canine mast cell tumors: Decreased expression and altered subcellular localization in Grade 3 tumors. The Veterinary Journal, v. 194, n. 3, p. 405–411, dez. 2012. MAGLENNON, G. A. et al. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours*. Veterinary and Comparative Oncology, v. 6, n. 4, p. 268–274, dez. 2008. MALCOLM, E. L. et al. Diagnostic value of vertebral left atrial size as determined from thoracic radiographs for assessment of left atrial size in dogs with myxomatous mitral valve disease. Journal of the American Veterinary Medical Association, v. 253, n. 8, p. 1038– 1045, 15 out. 2018. MARCONATO, L. et al. Clinicopathological Features and Outcome for Dogs with Mast Cell Tumors and Bone Marrow Involvement. Journal of Veterinary Internal Medicine, v. 22, n. 4, p. 1001–1007, jul. 2008. MARCONATO, L. et al. Adjuvant medical therapy provides no therapeutic benefit in the treatment of dogs with low‐grade mast cell tumours and early nodal metastasis undergoing surgery. Veterinary and Comparative Oncology, v. 18, n. 3, p. 409–415, 17 set. 2020. MASON, S. L. et al. Outcomes of adjunctive radiation therapy for the treatment of mast cell tumors in dogs and assessment of toxicity: A multicenter observational study of 300 dogs. Journal of Veterinary Internal Medicine, v. 35, n. 6, p. 2853–2864, 21 nov. 2021. MCCAW, D. L. et al. Response of Canine Mast Cell Tumors to Treatment With Oral 93 Prednisone. Journal of Veterinary Internal Medicine, v. 8, n. 6, p. 406–408, nov. 1994. MELO, S. R. et al. Immunohistochemical Expression of Vascular Endothelial Growth Factor as a Prognostic Marker for Canine Mast Cell Tumors. Topics in Companion Animal Medicine, v. 42, p. 100506, mar. 2021. MENDEZ, S. E. et al. Treating the locoregional lymph nodes with radiation and/or surgery significantly improves outcome in dogs with high‐grade mast cell tumours. Veterinary and Comparative Oncology, v. 18, n. 2, p. 239–246, 29 jun. 2020. MILA, H. et al. Differential impact of birth weight and early growth on neonatal mortality in puppies. Journal of Animal Science, v. 93, n. 9, p. 4436–4442, 1 set. 2015. MILLER, J. et al. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors. Frontiers in Veterinary Science, v. 6, 9 abr. 2019. MOCHIZUKI, H. et al. Association of breed and histopathological grade in canine mast cell tumours. Veterinary and Comparative Oncology, v. 15, n. 3, p. 829–839, set. 2017. MOONEY, C. Canine hypothyroidism: A review of aetiology and diagnosis. New Zealand Veterinary Journal, v. 59, n. 3, p. 105–114, maio 2011. MOSHREF, M. et al. Concise Review: Canine Diabetes Mellitus as a Translational Model for Innovative Regenerative Medicine Approaches. Stem Cells Translational Medicine, v. 8, n. 5, p. 450–455, 1 maio 2019. MURPHY, S. et al. Effects of stage and number of tumours on prognosis of dogs with cutaneous mast cell tumours. Veterinary Record, v. 158, n. 9, p. 287–291, mar. 2006. MUSSER, M. et al. Marked paraneoplastic hypereosinophilia associated with a low‐grade, metastatic canine mast cell tumour. Veterinary Record Case Reports, v. 6, n. 2, 26 set. 2018. NAKANO, Y. et al. Imatinib Responsiveness in Canine Mast Cell Tumors Carrying Novel Mutations of c-KIT Exon 11. Journal of Veterinary Medical Science, v. 76, n. 4, p. 545–548, 2014. NARDI, A. B. DE et al. Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors. Cells, v. 11, n. 4, p. 1–37, 2022. NEEL, J. A.; SNYDER, L.; GRINDEM, C. B. Thrombocytosis: a retrospective study of 165 94 dogs. Veterinary Clinical Pathology, v. 41, n. 2, p. 216–222, jun. 2012. NEGASEE, K. A. Hepatic Diseases in Canine and Feline: A Review. Veterinary Medicine – Open Journal, v. 6, n. 1, p. 22–31, 4 set. 2021. NEGRU, M. et al. Epidemiological study of the canine cutaneus mast cell tumor. Rev Rom Med Ve, v. 31, n. 2, p. 6–10, 2021. NEMEC, A. et al. Electroporation-Based Treatments in Small Animal Veterinary Oral and Maxillofacial Oncology. Frontiers in Veterinary Science, v. 7, n. 575911, p. 1–17, 29 set. 2020. NORTHRUP, N. C. et al. Iridium-192 Interstitial Brachytherapy as Adjunctive Treatment for Canine Cutaneous Mast Cell Tumors. Journal of the American Animal Hospital Association, v. 40, n. 4, p. 309–315, 1 jul. 2004. O’NEILL, D. G. et al. Longevity and mortality of owned dogs in England. The Veterinary Journal, v. 198, n. 3, p. 638–643, dez. 2013. OLIVEIRA, M. T. et al. Canine and Feline Cutaneous Mast Cell Tumor: A Comprehensive Review of Treatments and Outcomes. Topics in Companion Animal Medicine, v. 41, p. 100472, nov. 2020. OLSEN, J. A. et al. Combination vinblastine, prednisolone and toceranib phosphate for treatment of grade II and III mast cell tumours in dogs. Veterinary Medicine and Science, v. 4, n. 3, p. 237–251, ago. 2018. OWEN, L. TNM Classification of tumours in domestic animals. World Health Organisation, p. 1–52, 1980. PANINÁROVÁ, M. et al. Congenital and acquired anomalies of the caudal vertebrae in dogs: Radiographic classification and prevalence evaluation. Acta Veterinaria Hungarica, v. 64, n. 3, p. 330–339, set. 2016. PANIZZA, B. J. et al. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). EBioMedicine, v. 50, p. 433–441, dez. 2019. PATNAIK, A. K.; EHLER, W. J.; MACEWEN, E. G. Canine Cutaneous Mast Cell Tumor: Morphologic Grading and Survival Time in 83 Dogs. Veterinary Pathology, v. 21, n. 5, p. 95 469–474, 26 set. 1984. PAVLIN, D. et al. Electrogene therapy with interleukin-12 in canine mast cell tumors. Radiology and Oncology, v. 45, n. 1, 1 jan. 2011. PAVLIN, D.; CEMAZAR, M.; TOZON, N. Electrochemogene Therapy as an Effective and Safe Treatment of Canine Cutaneous Mast Cell Tumors. 1st World Congress on Electroporation and Pulsed Electric Fields in Biology, Medicine and Food & Environmental Technologies. Anais...2016Disponível em: <http://link.springer.com/10.1007/978-981-287- 817-5_93> PEDRAZA, F.; GRANDI, F.; ROCHA, N. S. The need for cytologic/histologic correlation studies to establish a cytologic grading system for canine mast cell tumors in veterinary medicine. Veterinary Clinical Pathology, v. 40, n. 3, p. 280–281, set. 2011. PIERINI, A. et al. Epidemiology of breed-related mast cell tumour occurrence and prognostic significance of clinical features in a defined population of dogs in West-Central Italy. Veterinary Sciences, v. 6, n. 2, p. 2–9, 2019. POGGIANI, S. DOS S. C. et al. Canine Cutaneous Mast Cell Tumor: Biologic Behavior and Its Correlation with Prognostic Indicators. Open Journal of Veterinary Medicine, v. 02, n. 04, p. 255–261, 2012. POIRIER, V. J. et al. Radiation Therapy for Incompletely Excised Grade II Canine Mast Cell Tumors. Journal of the American Animal Hospital Association, v. 42, n. 6, p. 430–434, 1 nov. 2006. PRATSCHKE, K. M. et al. Evaluation of a modified proportional margins approach forsurgical resection of mast cell tumors in dogs: 40 cases (2008–2012). Journal of the American Veterinary Medical Association, v. 243, n. 10, p. 1436–1441, 15 nov. 2013. PREZIOSI, R.; SARLI, G.; PALTRINIERI, M. Prognostic Value of Intratumoral Vessel Density in Cutaneous Mast Cell Tumours of the Dog. Journal of Comparative Pathology, v. 130, n. 2–3, p. 143–151, fev. 2004. RANDALL, E. K. et al. The development of an indirect computed tomography lymphography protocol for sentinel lymph node detection in head and neck cancer and comparison to other sentinel lymph node mapping techniques. Veterinary and Comparative Oncology, v. 18, n. 4, p. 634–644, 25 dez. 2020. 96 RANGEL, M. M. M. et al. Electrochemotherapy in the treatment of neoplasms in dogs and cats. Austral Journal of Veterinary Sciences, v. 51, n. 2, p. 45–51, 2019. RASSNICK, K. M. et al. Treatment of Canine Mast Cell Tumors with CCNU (Lomustine). Journal of Veterinary Internal Medicine, v. 13, n. 6, p. 601, 1999. RASSNICK, K. M. et al. Efficacy of Vinblastine for Treatment of Canine Mast Cell Tumors. Journal of Veterinary Internal Medicine, v. 22, n. 6, p. 1390–1396, nov. 2008. RASSNICK, K. M. et al. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Veterinary and Comparative Oncology, v. 8, n. 2, p. 138–152, jun. 2010. REDDELL, P. et al. Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate. Journal of Veterinary Internal Medicine, v. 35, n. 1, p. 430–441, 12 jan. 2021. REYNOLDS, B. D. et al. Patient and tumour factors influencing canine mast cell tumour histological grade and mitotic index. Veterinary and Comparative Oncology, v. 17, n. 3, p. 338–344, 2019. RIGAS, K. et al. Mast cell tumours in dogs less than 12 months of age: a multi‐institutional retrospective study. Journal of Small Animal Practice, v. 61, n. 7, p. 449–457, 26 jul. 2020. RODIGHERI, S. M. et al. Neuropatia paraneoplásica associada ao mastocitoma canino. Ciência Rural, v. 38, n. 3, p. 819–822, jun. 2008. ROMANSIK, E. M. et al. Mitotic Index Is Predictive for Survival for Canine Cutaneous Mast Cell Tumors. Veterinary Pathology, v. 44, n. 3, p. 335–341, 26 maio 2007. RUNGSIPIPAT, A. et al. Clinical evaluation of canine mast cell tumor treatment between combined vinblastine and prednisolone and single prednisolone. Comparative Clinical Pathology, v. 18, n. 1, p. 77–84, 2 fev. 2009. SABATTINI, S. et al. Histologic Grading of Canine Mast Cell Tumor: : Is 2 Better Than 3? Veterinary Pathology, v. 52, n. 1, p. 70–73, 10 jan. 2015. SABATTINI, S. et al. A retrospective study on prophylactic regional lymphadenectomy versus nodal observation only in the management of dogs with stage I, completely resected, low-grade 97 cutaneous mast cell tumors. BMC Veterinary Research, v. 17, n. 1, p. 331, 15 dez. 2021. SARMA, K.; MONDAL, D. B.; SARAVANAN, M. Ultrasonographic changes in dogs naturally infected with tick borne intracellular diseases. Journal of Parasitic Diseases, v. 40, n. 2, p. 248–251, 1 jun. 2016. SAUNDERS, H. et al. Evaluation of a modified proportional margin approach for complete surgical excision of canine cutaneous mast cell tumours and its association with clinical outcome. Veterinary and Comparative Oncology, v. 19, n. 4, p. 604–615, 23 dez. 2021. SCHWAB, T. M. et al. Clinical Outcome for MCTs of Canine Pinnae Treated with Surgical Excision (2004–2008). Journal of the American Animal Hospital Association, v. 50, n. 3, p. 187–191, 1 maio 2014. SELMIC, L. E.; RUPLE, A. A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs. BMC Veterinary Research, v. 16, n. 1, p. 5, 6 dez. 2020. SERRA VARELA, J. C. et al. Tolerability of a rapid-escalation vinblastine-prednisolone protocol in dogs with mast cell tumours. Veterinary Medicine and Science, v. 2, n. 4, p. 266– 280, nov. 2016. SHOOP, S. J. et al. Prevalence and risk factors for mast cell tumours in dogsin England. Canine Genetics and Epidemiology, v. 2, n. 1, p. 1, 2015. SIMPSON, A. M. et al. Evaluation of surgical margins required for complete excision of cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association, v. 224, n. 2, p. 236–240, 1 jan. 2004. SIMPSON, M. et al. Age at gonadectomy and risk of overweight/obesity and orthopedic injury in a cohort of Golden Retrievers. PLOS ONE, v. 14, n. 7, p. e0209131, 17 jul. 2019. ŚMIECH, A. et al. Epidemiological study of canine mast cell tumours according to the histological malignancy grade. Polish Journal of Veterinary Sciences, v. 20, n. 3, p. 455–465, 2017. ŚMIECH, A. et al. Epidemiological assessment of the risk of canine mast cell tumours based on the Kiupel two-grade malignancy classification. Acta Veterinaria Scandinavica, v. 60, n. 1, p. 70, 3 dez. 2018. ŚMIECH, A. et al. Occurrence and distribution of canine cutaneous mast cell tumour 98 characteristics among predisposed breeds. Journal of Veterinary Research, v. 63, n. 1, p. 141– 148, 1 mar. 2019. SMITH, J. et al. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone. Veterinary and Comparative Oncology, v. 15, n. 1, p. 36–45, mar. 2015. SMRKOVSKI, O. A. et al. Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours. Veterinary and Comparative Oncology, v. 13, n. 3, p. 314–321, set. 2015. SONET, J. et al. Prospective evaluation of abdominal ultrasonographic findings in 35 dogs with leptospirosis. Veterinary Radiology & Ultrasound, v. 59, n. 1, p. 98–106, jan. 2018. SOUZA, A. C. F. et al. Mastocitoma cutâneo canino: estudo retrospectivo dos casos atendidos pelo Serviço de Oncologia do Hospital Veterinário da FCAV-Unesp, Campus Jaboticabal, de 2005 a 2015. Pesquisa Veterinária Brasileira, v. 38, n. 9, p. 1808–1817, set. 2018. SPUGNINI, E. P. et al. Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer research, v. 26, n. 6B, p. 4585–9, 2006. SPUGNINI, E. P. et al. Evaluation of Cisplatin as an Electrochemotherapy Agent for the Treatment of Incompletely Excised Mast Cell Tumors in Dogs. Journal of VeterinaryInternal Medicine, v. 25, n. 2, p. 407–411, mar. 2011. STANCLIFT, R. M.; GILSON, S. D. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association, v. 232, n. 1, p. 53–62, 1 jan. 2008. STREFEZZI, R. D. F. et al. The Value of Immunohistochemical Expression of BAX in Formulating a Prognosis for Canine Cutaneous Mast Cell Tumours. Journal of Comparative Pathology, v. 146, n. 4, p. 314–319, maio 2012. STREFEZZI, R. DE F. et al. Nuclear morphometry in cytopathology: A prognostic indicator for canine cutaneous mast cell tumors. Journal of Veterinary Diagnostic Investigation, v. 21, n. 6, p. 821–825, 2009. STRZALKA, W.; ZIEMIENOWICZ, A. Proliferating cell nuclear antigen (PCNA): a key factor in DNA replication and cell cycle regulation. Annals of Botany, v. 107, n. 7, p. 1127– 1140, maio 2011. 99 TAMLIN, V. et al. Prevalence of exon 11 internal tandem duplications in the C-KIT proto- oncogene in Australian canine mast cell tumours. Australian Veterinary Journal, v. 95, n. 10, p. 386–391, out. 2017. TAMLIN, V. S.; BOTTEMA, C. D. K.; PEASTON, A. E. Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment. Veterinary Medicine and Science, v. 6, n. 1, p. 3–18, 24 fev. 2019. TAMLIN, V. S.; BOTTEMA, C. D. K.; PEASTON, A. E. Comparative aspects of mast cell neoplasia in animals and the role of KIT in prognosis and treatment. Veterinary Medicine and Science, v. 6, n. 1, p. 3–18, 24 fev. 2020. TAYLOR, F. et al. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. Journal of Small Animal Practice, v. 50, n. 6, p. 284–289, 2009. THAMM, D. H. et al. Prognostic and predictive significance of KIT protein expression and c‐ kit gene mutation in canine cutaneous mast cell tumours: A consensus of the Oncology‐ Pathology Working Group. Veterinary and Comparative Oncology, v. 17, n. 4, p. 451–455, 9 dez. 2019. THAMM, D. H.; MAULDIN, E. A.; VAIL, D. M. Prednisone and Vinblastine Chemotherapy for Canine Mast Cell Tumor—41 Cases (1992–1997). Journal of Veterinary Internal Medicine, v. 13, n. 5, p. 491, 1999. THAMM, D. H.; TUREK, M. M.; VAIL, D. M. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 Cases. Journal of Veterinary Medical Science, v. 68, n. 6, p. 581–587, 2006. TIWARI, K. P. et al. Expression pattern of proliferating cell nuclear antigen (PCNA) in round cell tumors of dogs from Grenada, West Indies. Indian Journal of Veterinary Pathology, v. 40, n. 2, p. 144, 2016. TORRES DE LA RIVA, G. et al. Neutering Dogs: Effects on Joint Disorders and Cancers in Golden Retrievers. PLoS ONE, v. 8, n. 2, p. e55937, 13 fev. 2013. TOTHOVA, C.; NAGY, O.; KOVAC, G. Serum proteins and their diagnostic utility in veterinary medicine: a review. Veterinární medicína, v. 61, n. 9, p. 475–496, 30 set. 2016. TOZON, N. et al. Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats. Journal of Visualized Experiments, n. 116, p. 1–7, 24 out. 2016. 100 TURREL, J. M. et al. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. Journal of the American Veterinary Medical Association, v. 193, n. 8, p. 936–40, 15 out. 1988. VASCELLARI, M. et al. Expression of Ki67, BCL-2, and COX-2 in Canine Cutaneous Mast Cell Tumors. Veterinary Pathology, v. 50, n. 1, p. 110–121, 6 jan. 2013. VICKERY, K. R. et al. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Veterinary and Comparative Oncology, v. 6, n. 2, p. 111–119, jun. 2008. VILLAMIL, J. A. et al. Identification of the most common cutaneous neoplasms in dogs and evaluation of breed and age distributions for selected neoplasms. Journal of the American Veterinary Medical Association, v. 239, n. 7, p. 960–965, 1 out. 2011. VOZDOVA, M. et al. Prevalence and prognostic value of c-kit and TP53 mutations in canine mast cell tumours. The Veterinary Journal, v. 247, p. 71–74, maio 2019. VOZDOVA, M. et al. Recurrent gene mutations detected in canine mast cell tumours by next generation sequencing. Veterinary and Comparative Oncology, v. 18, n. 4, p. 509–518, 7 dez. 2020. WARLAND, J. et al. The utility of staging in canine mast cell tumours. Veterinary and Comparative Oncology, v. 12, n. 4, p. 287–298, dez. 2014. WARLAND, J.; DOBSON, J. Breed predispositions in canine mast cell tumour: A single centre experience in the United Kingdom. The Veterinary Journal, v. 197, n. 2, p. 496–498, ago. 2013. WARRY, E. et al. Pharmacokinetics of Cyclophosphamide after Oral and Intravenous Administration to Dogs with Lymphoma. Journal of Veterinary Internal Medicine, v. 25, n. 4, p. 903–908, jul. 2011. WEBSTER, J. D. et al. The Role of c-KIT in Tumorigenesis: Evaluation in Canine Cutaneous Mast Cell Tumors. Neoplasia, v. 8, n. 2, p. 104–111, fev. 2006. WEBSTER, J. D. et al. Cellular Proliferation in Canine Cutaneous Mast Cell Tumors: Associations with c-KIT and Its Role in Prognostication. Veterinary Pathology, v. 44, n. 3, p. 298–308, 26 maio 2007. WEBSTER, J. D. et al. Evaluation of prognostic markers for Canine mast cell tumors treated 101 with vinblastine and prednisone. BMC Veterinary Research, v. 4, p. 1–8, 2008. WEISHAAR, K. M. et al. c-Kit Mutation and Localization Status as Response Predictors in Mast Cell Tumors in Dogs Treated with Prednisone and Toceranib or Vinblastine. Journal of Veterinary Internal Medicine, v. 32, n. 1, p. 394–405, jan. 2018. WELLE, M. M. et al. Canine mast cell tumours: a review of the pathogenesis, clinical features, pathology and treatment. Veterinary Dermatology, v. 19, n. 6, p. 321–339, dez. 2008. WHITE, C. R. et al. Cutaneous MCTs: Associations with Spay/Neuter Status, Breed, Body Size, and Phylogenetic Cluster. Journal of the American Animal Hospital Association, v. 47, n. 3, p. 210–216, 1 maio 2011. WILLMANN, M. et al. Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. Frontiers in Veterinary Science, v. 8, 10 dez. 2021. WOOLCOCK, A. . et al. Thrombocytosis in 715 Dogs (2011-2015). Journal of Veterinary Internal Medicine, v. 31, n. 6, p. 1691–1699, nov. 2017. WORLEY, D. R. Incorporation ofsentinel lymph node mapping in dogs with mast cell tumours: 20 consecutive procedures. Veterinary and Comparative Oncology, v. 12, n. 3, p. 215–226, set. 2014. WOUDA, R. M. et al. Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997–2012). Journal of the American Veterinary Medical Association, v. 246, n. 11, p. 1230–1237, jun. 2015. YAMADA, O. et al. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A&gt;T mutation via suppression of constitutive KIT activation. Veterinary Immunology and Immunopathology, v. 142, n. 1–2, p. 101–106, jul. 2011. YOON, J.-S. et al. Severe pulmonary mineralization in a dog with pituitary-dependent hyperadrenocorticism: a case report. Korean Journal of Veterinary Research, v. 59, n. 4, p. 223–226, 31 dez. 2019. ZEMKE, D.; YAMINI, B.; YUZBASIYAN-GURKAN, V. Mutations in the Juxtamembrane Domain of c- KIT Are Associated with Higher Grade Mast Cell Tumors in Dogs. Veterinary Pathology, v. 39, n. 5, p. 529–535, 26 set. 2002. ZINK, M. C. et al. Evaluation of the risk and age of onset of cancer and behavioral disorders in 102 gonadectomized Vizslas. Journal of the American Veterinary Medical Association, v. 244, n. 3, p. 309–319, 1 fev. 2014.pt_BR
dc.subject.cnpqMedicina Veterináriapt_BR
Appears in Collections:Doutorado em Ciências Veterinárias

Se for cadastrado no RIMA, poderá receber informações por email.
Se ainda não tem uma conta, cadastre-se aqui!

Files in This Item:
File Description SizeFormat 
2023 - Monica Yamile Padilla Barreto.Pdf1.6 MBAdobe PDFThumbnail
View/Open
Show simple item record


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.